Zumutor is developing a comprehensive drug product portfolio that utilizes the strengths of our proprietary technology platforms for the treatment of cancer and other serious diseases. The current product focus can be divided into two major categories.

  • Novel Biologics

Our Immune-Onco portfolio delves into new biomarkers for NK cell based cancer immunotherapy, emerging area of transformational therapies. Zumutor is developing novel clinically proven combinatorial immune therapy using IP driven Antibody Engineering Platforms which targets primarily innate immunity and regulation of the tumor microenvironment. Our portfolio constitutes multiple market validated Immune-Onco targets, scheduled to enter preclinical study by end of 2017.

  • Biosimilars

We have developed several biosimilar molecules and which are ready for licensing. We follow QbD approach for process development of biosimilars. Our philosophy is to develop “highly similar” biosimilar product using “Totality of Evidence” approach for developed and emerging markets. Our QTPP is established using several different batches of innovator’s molecule. We have capabilities for developing biosimilar using both microbial and mammalian platform. We will develop future biosimilar molecules in collaboration with partner.

    • Proposed biosimilar to Exendin-4 and Trastuzumab using microbial and mammalian cell line, respectively have been developed. Exendin 4 (marketed as Byetta®), a GLP1 analog is prescribed for twice a day injection for diabetics. The proposed biosimilar product has been extensively characterized to establish biosimilarity and is ready for pre-clinical studies – animal toxicity and pharmacokinetics studies
    • Trastuzumab is a recombinant humanized IgG1 monoclonal antibody that binds specifically to extracellular domain of human epidermal growth factor receptor 2 (HER2); indicated for adjuvant treatment of HER2-overexpressing breast cancer. After extensive process development and characterization, this molecule is ready for animal studies. In vivo efficacy study of proposed biosimilar to Trastuzumab in PDX Model has been successfully completed